Canadian Optically-guided approach for Oral Lesions Surgical (COOLS) trial: study protocol for a randomized controlled trial
1 Department of Oral Biological and Medical Science, The University of British Columbia, Wesbrook Mall, Vancouver, Canada
2 Department of Surgery, The University of British Columbia, West 10th Avenue, Vancouver, Canada
3 Department of Statistics, The University of British Columbia, Agricultural Road, Vancouver, Canada
4 Integrative Oncology, British Columbia Cancer Agency/Research Centre, West 10th Avenue, Vancouver, Canada
5 Cancer Control Research, British Columbia Cancer Agency/Research Centre, West 10th Avenue, Vancouver, Canada
6 Otolaryngology- Head & Neck Surgery, Vancouver General Hospital, Laurel Street, Vancouver, Canada
7 Centre for Clinical Epidemiology and Evaluation, Vancouver General Hospital, West 10th Avenue, Vancouver, Canada
8 Anatomical Pathology, Vancouver General Hospital, Laurel Street, Vancouver, Canada
9 MD Anderson Cancer Center, University of Texas, Holcombe Boulevard, Texas, USA
10 Biomedical Physiology and Kinesiology, Simon Fraser University, University Drive, Burnaby, Canada
BMC Cancer 2011, 11:462 doi:10.1186/1471-2407-11-462Published: 25 October 2011
Oral cancer is a major health problem worldwide. The 5-year survival rate ranges from 30-60%, and has remained unchanged in the past few decades. This is mainly due to late diagnosis and high recurrence of the disease. Of the patients who receive treatment, up to one third suffer from a recurrence or a second primary tumor. It is apparent that one major cause of disease recurrence is clinically unrecognized field changes which extend beyond the visible tumor boundary. We have previously developed an approach using fluorescence visualization (FV) technology to improve the recognition of the field at risk surrounding a visible oral cancer that needs to be removed and preliminary results have shown a significant reduction in recurrence rates.
This paper describes the study design of a randomized, multi-centre, double blind, controlled surgical trial, the COOLS trial. Nine institutions across Canada will recruit a total of 400 patients with oral severe dysplasia or carcinoma in situ (N = 160) and invasive squamous cell carcinoma (N = 240). Patients will be stratified by participating institution and histology grade and randomized equally into FV-guided surgery (experimental arm) or white light-guided surgery (control arm). The primary endpoint is a composite of recurrence at or 1 cm within the previous surgery site with 1) the same or higher grade histology compared to the initial diagnosis (i.e., the diagnosis used for randomization);
In this paper we described the strategies, novelty, and challenges of this unique trial involving a surgical approach guided by the FV technology. The success of the trial requires training, coordination, and quality assurance across multiple sites within Canada. The COOLS trial, an example of translational research, may result in reduced recurrence rates following surgical treatment of early-stage oral cancer with significant impacts on survival, morbidity, patients' quality of life and the cost to the health care system.